Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Comolli

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 18, 2000
Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patientsF Baldanti, S Paolucci, R Maserati, et al.
The New Microbiologica|July 1, 1993
Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothersC Belloni, P Orsolini, M Martinetti, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 11, 2011
Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantationG Gerna, D Lilleri, A Chiesa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2001
Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAARTG Gerna, G Piccinini, E Genini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2022
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatmentA Lasagna, F Bergami, D Lilleri, et al.
ESMO Open|August 27, 2022
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concernA Lasagna, F Bergami, D Lilleri, et al.
ESMO Open|April 15, 2022
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort studyA Lasagna, F Bergami, D Lilleri, et al.
ESMO Open|January 1, 2022
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-upA Lasagna, D Lilleri, F Agustoni, et al.
ESMO Open|September 20, 2021
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort studyA Lasagna, F Agustoni, E Percivalle, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|July 18, 2000
Higher short-term virologic efficacy of three-class versus two-class highly active antiretroviral salvage therapy in HIV-infected patientsF Baldanti, S Paolucci, R Maserati, et al.
The New Microbiologica|July 1, 1993
Control of hepatitis B: evaluation of two different vaccinal schedules in newborns from HBsAg negative mothersC Belloni, P Orsolini, M Martinetti, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|August 11, 2011
Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantationG Gerna, D Lilleri, A Chiesa, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 15, 2001
Declining levels of rescued lymphoproliferative response to human cytomegalovirus (HCMV) in AIDS patients with or without HCMV disease following long-term HAARTG Gerna, G Piccinini, E Genini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2022
Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatmentA Lasagna, F Bergami, D Lilleri, et al.
ESMO Open|August 27, 2022
Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concernA Lasagna, F Bergami, D Lilleri, et al.
ESMO Open|April 15, 2022
Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort studyA Lasagna, F Bergami, D Lilleri, et al.
ESMO Open|January 1, 2022
Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-upA Lasagna, D Lilleri, F Agustoni, et al.
ESMO Open|September 20, 2021
A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort studyA Lasagna, F Agustoni, E Percivalle, et al.
Pageof 3